Navigation Links
Novel combination therapy shuts down escape route, killing glioblastoma tumor cells
Date:2/26/2013

t became clear that the glioblastoma cells massively regulated PML enabling them to escape the effects of mTOR inhibitor therapy," reported senior author Paul Mischel, MD, Ludwig Institute member based at the University of California at San Diego.

"Our team hypothesized that if we could use a pharmacological approach to get rid of PML and combine it with an mTOR inhibitor, it could change the response from halting growth to cell death. The question was how?" added Mischel.

Previous research had shown that the use of low-dose arsenic could cause degradation of the PML protein in patients with leukemia. The team hypothesized that if arsenic could degrade PML, it may reverse resistance to mTOR inhibitors. The combination of mTOR and low-dose arsenic in mice indeed showed a synergistic effect, with massive tumor cell death along with very significant shrinkage of the tumor in mice with no ill side effects.

"Current therapy upregulates PML, turning off the mTOR signaling pathway. The tumor cells hide, waiting for the target signal to return," said Mischel. "When low-dose arsenic is added, not only does it stop the cell from returning, it shuts down the escape route killing the tumor cell."

These results present the first clinical evidence that mTOR inhibition promotes PML upregulation in mice and patients, and that it mediates drug resistance. The clinical relevance was confirmed when researchers looked at before- and after-treatment tissue samples from patients treated with mTOR inhibitors, confirming that PML goes up significantly in post treatment of mTOR inhibitors.

"These data suggest a new approach for potential treatment of glioblastoma," said Mischel. "We are moving forward to test that possibility in people."

Post-doctoral students Akio Iwanami and Beatrice Gini from the Mischel lab as well as Ciro Zanca from the Furnari/Cavenee lab, also contributed significantly to this paper.


'/>"/>
Contact: Rachel Steinhardt
rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Researchers discover novel therapy for Crohns disease
2. New clinical trial explores novel noninvasive colon cancer screening test
3. Notre Dame researchers using novel method to combat malaria drug resistance
4. Unique adaptations to a symbiotic lifestyle reveal novel targets for aphid insecticides
5. Key proteins newly discovered form and function may provide novel cancer treatment target
6. Novel discovery by NUS scientists paves the way for more effective treatment of cancers
7. London researchers discover novel mechanism involved in key immune response
8. Mexican rock heroes trial novel green trading system
9. VTT and GE Healthcare developing novel biomarkers to predict Alzheimers disease
10. Cleveland Clinic researchers receive $5 million grant to discover novel pathways to heart disease
11. Novel nano-structures to realize hydrogens energy potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... -- When we want to listen carefully to someone, ... second thing we do is stop moving altogether. This ... generated by our own movements. , This interplay between ... the brain. Indeed, indirect evidence has long suggested that ... the auditory cortex, which gives rise to our conscious ...
(Date:8/27/2014)... Aug. 27, 2014 /PRNewswire-iReach/ -- The IEEE Engineering in ... th Annual International Conference (EMBC,14), this year being ... Chicago, Illinois , from Tuesday, August ... leaders, students, and industry professionals in science, medicine, and ... http://photos.prnewswire.com/prnh/20140827/140333 This year,s conference ...
(Date:8/27/2014)... deadly disease that exists as five strains, none of ... strains is the Sudan ebolavirus (SUDV). Although not the ... illness, even as recently as 2012. In a new ... , researchers now report a possible therapy that could ... Dye, Sachdev Sidhu, Jonathan Lai and colleagues explain that ...
Breaking Biology News(10 mins):Stop and listen: Study shows how movement affects hearing 2Stop and listen: Study shows how movement affects hearing 3Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 3Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks 2
... Do you want that in a pill or a shot? ... choice. The problem with administering many medications orally is that ... site in the gastrointestinal tract where the medicine can be ... by Brown University researchers could solve the problem by safely ...
... with common blood pressure medications may cause hypotension ... older patients, requiring hospitalization, according to a study ... Association Journal ) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj100702.pdf ... are among the most widely prescribed antibiotics, with ...
... Stanford University School of Medicine, in collaboration with BioParadox, ... plasma as a promising biologic treatment for myocardial infarction ... online in Cardiovascular Revascularization Medicine and will ... Therapy for Cardiovascular Disease at Columbia University Medical Center, ...
Cached Biology News:Magnetically controlled pill could boost body's absorption of drugs 2RevaTen platelet-rich plasma shows promise as potential treatment for heart attacks 2
(Date:8/27/2014)... , Aug. 27, 2014 Research and ... "Global Enzyme for Pulp & Paper Industry Report 2014" ... Global Enzyme for Pulp & Paper Industry Report 2014 ... state of the global enzyme for pulp & paper ... of the industry including definitions, classifications, applications and industry ...
(Date:8/27/2014)... Florida (PRWEB) August 27, 2014 ... (SCI) is announcing the creation of the Sancilio ... to take the SCI’s philosophy of looking to ... research and development actions are based on sound ... new Scientific Advisory Board provides a vehicle for ...
(Date:8/27/2014)... College, PA (PRWEB) August 27, 2014 ... Simulation Software with new features for the biomedical ... is an enhanced Biological Thermal Sensor, exclusive to the ... a specialty version of XFdtd, developed to calculate the ... export functionality has been added to all versions to ...
(Date:8/26/2014)... ANGELES , Aug. 26, 2014  NeuroSigma, Inc., ... company established to develop bioelectronic technologies, today announced that ... with the U.S. Securities and Exchange Commission relating to ... The number of shares to be offered and the ... been determined. Jefferies LLC will act as ...
Breaking Biology Technology:Global Enzyme for Pulp & Paper Industry Report 2014 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 2Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 3
... Sept. 23 S*BIO Pte Ltd today announced ... will support the continued development of S*BIO,s clinical ... reflects the international investment community,s strong interest in ... clinical development and the quality of our various ...
... China, Sept. 22 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, ... ), which develops, manufactures, and markets specialty pharmaceutical ... has successfully completed Phase I clinical trials of ... Cephalosporin continues to be the most widely prescribed ...
... VANCOUVER, Sept. 22 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ... of results from a randomized Phase 2 trial ... results showed a survival benefit with the investigational ... cancer. The median overall survival for patients who ...
Cached Biology Technology:S*BIO Announces US$5 Million Investment by Mitsui Ventures 2S*BIO Announces US$5 Million Investment by Mitsui Ventures 3China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 2China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 3China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 4OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial 2OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial 3OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial 4OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial 5
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
ID clarifier: With ethidium bromide (50 μg/ml)...
... in DMEM and harvested at the log phase ... antigens in their native forms, cells were fixed ... a 12-well (5 mm) adhesive coated slide, with ... attachment and to minimize background staining. Each ...
Biology Products: